Siemens Brings Its Latest Innovations in Laboratory Diagnostics to MEDLAB Middle East 2022

Siemens demonstrated its Atellica hematology portfolio that pairs automation, intelligence, and extended parameters to streamline operations and support accurate clinical decision-making. The company displayed its two new flagship hematology analyzers - Atellica HEMA 570 and 580 - that are designed to deliver reliable performance targeted for high volume routine workloads. Also on display was the Atellica Solution comprising flexible, scalable, automation-ready immunoassay and chemistry analyzers with integrated automation. Atellica Integrated Automation (AIA) on the Atellica Solution consolidates revolutionary sample management technology, intelligent software, and IT to provide workflow efficiency with the flexibility to add decapping with little or no additional footprint.

In addition, Siemens highlighted its Sysmex CN-3000 and CN-6000 fully automated, mid- and high-volume coagulation analyzers that help meet the small-sized, mid- and high-volume hemostasis testing solutions to tackle big lab challenges. Giants on the inside, combining size, speed, intelligence, and flexibility, the Sysmex CN Systems help transform care delivery through improved workforce productivity.

Siemens demonstrated how Atellica Diagnostics IT provides scalable, easy-to-use solutions to simplify tasks and maximize the effectiveness of the laboratory and its staff. Viewers learnt how Atellica Diagnostics IT can enhance visibility, automate processes, and centralize management across instruments, automation, sites, and networks. Siemens also demonstrated Atellica Inventory Manager, its real-time automated inventory management solution that provides automated, real-time control of reagents and consumables across multiple locations to reduce costs, save time, and improve lab quality. Other lab products highlighted by Siemens at MEDLAB Middle East 2022 included the INNOVANCE VWF Ac assay which sets a new standard in VWF activity determination and its robust menu of inflammatory markers (including a key marker, IL-6) and other lab tests to assess tissue and organ damage that can help clinicians understand the severity of the COVID-19 disease as well as implement timely interventions for patients at risk for cytokine storm.

Related Links:
Siemens Healthineers